The target audience for this program is retina specialists and general ophthalmologists specializing in the treatment of retina disease.
Non Infectious Posterior Uveitis: The Rational for Steroid Use Webinar
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Describe key factors in the differential diagnosis of noninfectious posterior uveitis
- Discuss current treatment guidelines and the side effects associated with them
- Evaluate the safety and efficacy of different treatment modalities for noninfectious posterior uveitis, including corticosteroids, sustained-release implants, immunomodulatory/immunosuppressive agents, and biologics
- Assess clinical trial data pertaining to new therapies, including steroid-sparing treatments
Accreditation
Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and Retina Today and New Retina MD. Credit Designation Statement Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit.™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Grantor Statement This continuing medical education activity is supported through an educational grant from Santen Pharmaceutical Co., Ltd.
Disclaimer
It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty members have the following financial relationships with commercial interests: Thomas Albini, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie, Inc.; Allergan, Inc; Bausch + Lomb; and Santen Pharmaceutical Co., Ltd. Steven Yeh, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch+ Lomb; Clearside Biomedical, Inc.; and Santen Pharmaceutical Co., Ltd. Grant/Research Support: Alcon Research Institute; Clearside Biomedical, Inc.; NIH; and Xoma Ltd. Editorial Support Cheryl Cavanaugh, MS, Evolve Medical Education LLC; Emily Feinman, Retina Today and New Retina MD; and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report. Rishi Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech, Inc; Regeneron Pharmaceuticals, Inc.; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal - CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit

























